Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults: A Cluster Randomized Crossover Study - Takeaways - MDSpire

Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults: A Cluster Randomized Crossover Study

  • By

  • Amber Hsiao

  • Thomas Leong

  • Bruce Fireman

  • John Hansen

  • Ousseny Zerbo

  • Karen B. Jacobson

  • Lauren D. Liao

  • Mendel D. M. Haag

  • Ian McGovern

  • Bin Zhang

  • Juliet Dang

  • Nicola P. Klein

  • May 4, 2026

  • 0 min

Share

  • 1

    Influenza significantly impacts older adults, with 70-85% of related deaths occurring in those aged 65 and older.

  • 2

    The US ACIP recommends adjuvanted or high-dose influenza vaccines for adults 65 years and older to improve immune response.

  • 3

    A study was conducted to compare the relative vaccine effectiveness of adjuvanted versus high-dose influenza vaccines in older adults.

  • 4

    The study utilized a cluster randomized crossover design within Kaiser Permanente Northern California to assess vaccine effectiveness.

  • 5

    The primary outcome measured was PCR-confirmed influenza occurring 14 days or more after vaccination.

Original Source(s)

Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults: A Cluster Randomized Crossover Study

  • by Amber Hsiao, Thomas Leong, Bruce Fireman, John Hansen, Ousseny Zerbo, Karen B. Jacobson, Lauren D. Liao, Mendel D. M. Haag, Ian McGovern, Bin Zhang, Juliet Dang, Nicola P. Klein

  • May 4, 2026

Related Content

Correction: One hundred years of BCG: the journey of tuberculosis vaccination in Brazil

AI Aid Shows Uneven Reporting Gains

Time savings varied by baseline writing time and radiologist in a proof-of-concept study

Side Effects: Nobody Trained for This

Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.